Advancing Innovation: Peptides for Treating Cancers and other Proliferative Disorders
A quick-read Asset Development funding update
What is the technology?
Peptides Targeting Inositols Mediated Proliferative Signaling for Treating Cancers and other Proliferative Disorders
Who is on the inventing team?
- Olga Rafikova, Associate Professor, College of Medicine – Tucson
- Ruslan Rafikov, Associate Professor, College of Medicine – Tucson
How were Asset Development funds used?
Funds were used to hire an outside contract research organization to run tests to evaluate how effective the peptides developed by Rafikova and Rafikov would be in treating a variety of cancers. Over 140 different cancers that appear in 17 organs were tested.
What was the outcome?
The assays showed that the UArizona peptides were most effective in lung, leukemia, colon, and gastrointestinal cancers. They provided essential data to help the team develop a clearer market strategy that will maximize the impact of the technology for doctors and patients. The data will also be useful as the team moves forward toward launching a startup, applying for further grant funding, and developing potential partnerships with pharmaceutical companies.
Want to learn how you can advance your novel discovery for a better world?
Asset Development funding is a program open to all UArizona inventors. Funds are available now.